11-12 September 2018 //  Lancaster Royal Hotel, London


Andres Gutierrez

Dr Andres Gutierrez

Chief Medical Officer, Oncolytics Biotech Inc

Dr. Andres A. Gutierrez has served as Chief Medical Officer at Oncolytics Biotech Inc since 2016. He has previously held progressively senior clinical development positions designing and implementing both early and later-stage oncology clinical studies at diverse companies including Bristol-Myers Squibb, Sellas Life Sciences group, Sunesis Pharmaceuticals Inc., Biomarin Pharmaceutical Inc. and Proteolix.  In pharma, Dr Gutierrez has contributed in the development of carfilzomib in multiple myeloma, a PARP inhibitor (Talazoparib) in breast cancer and anti-LAG3 antibodies in various tumor types, among other projects in immuno oncology.  Over his career, he has authored and co-authored more than 90 peer-reviewed publications and abstracts and presented at numerous conferences. He is board certified in internal medicine with an MD and a PhD in Biomedical Sciences from the National Autonomous University of Mexico and a fellowship in medical oncology from the Hammersmith Hospital-RPMS, London UK.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad